Literature DB >> 19055665

Longitudinal follow up of elevated pulmonary artery pressures in children with sickle cell disease.

Farzana D Pashankar1, Judith Carbonella, Alia Bazzy-Asaad, Alan Friedman.   

Abstract

Elevated pulmonary artery pressures (PAP) occur in approximately 30% of children with sickle cell disease. In adults, pulmonary hypertension is significantly associated with mortality. There are no data on the long term significance in children. Nineteen children with SS/Sbeta(0) thalassaemia had elevated PAP, defined as tricuspid regurgitant jet velocity (TRV) > or =2.5 m/s on screening echocardiograms. They were prospectively followed for 23 months (range 19-31 months). Patients with initial TRV > or = 3 or TRV > or = 2.5 m/s on repeat echocardiogram had cardiopulmonary evaluation and were offered treatment with hydroxyurea. Associated conditions like asthma and obstructive sleep apnea were treated. 18/19 patients had follow-up echocardiograms. These showed normalization of TRV in 8 patients. Risk factors associated with persistent elevation were higher TRV on initial echocardiogram (P = 0.01), lower haemoglobin (P = 0.003) and lower oxygen saturation (P = 0.03). Five patients with persistently elevated PAP were treated with hydroxyurea. Mean right ventricular pressure dropped from 40.16 to 29.26 (P = 0.017) after 3-6 months and to 23.6 mmHg (P = 0.002) after 9-12 months on treatment. In conclusion (i) At borderline elevation of TRV there is intrapatient variability and echocardiograms should be repeated for confirmation. (ii) Elevated PAP are reversible in children with early detection and treatment with hydroxyurea.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19055665     DOI: 10.1111/j.1365-2141.2008.07501.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  25 in total

1.  Doppler-defined pulmonary hypertension and the risk of death in children with sickle cell disease followed for a mean of three years.

Authors:  Margaret T Lee; Tania Small; Muhammad A Khan; Erika B Rosenzweig; Robyn J Barst; Gary M Brittenham
Journal:  Br J Haematol       Date:  2009-06-25       Impact factor: 6.998

2.  Periodic limb movements and disrupted sleep in children with sickle cell disease.

Authors:  Valerie E Rogers; Carole L Marcus; Abbas F Jawad; Kim Smith-Whitley; Kwaku Ohene-Frempong; Cheryl Bowdre; Julian Allen; Raanan Arens; Thornton B A Mason
Journal:  Sleep       Date:  2011-07-01       Impact factor: 5.849

3.  Hemodynamic predictors of mortality in adults with sickle cell disease.

Authors:  Alem Mehari; Shoaib Alam; Xin Tian; Michael J Cuttica; Christopher F Barnett; George Miles; Dihua Xu; Catherine Seamon; Patricia Adams-Graves; Oswaldo L Castro; Caterina P Minniti; Vandana Sachdev; James G Taylor; Gregory J Kato; Roberto F Machado
Journal:  Am J Respir Crit Care Med       Date:  2013-04-15       Impact factor: 21.405

4.  An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease.

Authors:  Elizabeth S Klings; Roberto F Machado; Robyn J Barst; Claudia R Morris; Kamal K Mubarak; Victor R Gordeuk; Gregory J Kato; Kenneth I Ataga; J Simon Gibbs; Oswaldo Castro; Erika B Rosenzweig; Namita Sood; Lewis Hsu; Kevin C Wilson; Marilyn J Telen; Laura M Decastro; Lakshmanan Krishnamurti; Martin H Steinberg; David B Badesch; Mark T Gladwin
Journal:  Am J Respir Crit Care Med       Date:  2014-03-15       Impact factor: 21.405

5.  Longitudinal effect of disease-modifying therapy on tricuspid regurgitant velocity in children with sickle cell anemia.

Authors:  Parul Rai; Vijaya M Joshi; Jason F Goldberg; Amber M Yates; Victoria I Okhomina; Rhiannon Penkert; Kenneth I Ataga; Guolian Kang; Jane S Hankins
Journal:  Blood Adv       Date:  2021-01-12

6.  NT-pro brain natriuretic peptide levels and the risk of death in the cooperative study of sickle cell disease.

Authors:  Roberto F Machado; Mariana Hildesheim; Laurel Mendelsohn; Alan T Remaley; Gregory J Kato; Mark T Gladwin
Journal:  Br J Haematol       Date:  2011-06-21       Impact factor: 6.998

7.  Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease.

Authors:  Caterina P Minniti; Roberto F Machado; Wynona A Coles; Vandana Sachdev; Mark T Gladwin; Gregory J Kato
Journal:  Br J Haematol       Date:  2009-09-22       Impact factor: 6.998

8.  Prospective evaluation of haemoglobin oxygen saturation at rest and after exercise in paediatric sickle cell disease patients.

Authors:  Andrew Campbell; Caterina P Minniti; Mehdi Nouraie; Manuel Arteta; Sohail Rana; Onyinye Onyekwere; Craig Sable; Gregory Ensing; Niti Dham; Lori Luchtman-Jones; Gregory J Kato; Mark T Gladwin; Oswaldo L Castro; Victor R Gordeuk
Journal:  Br J Haematol       Date:  2009-08-19       Impact factor: 6.998

9.  Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions.

Authors:  Gregory J Kato; Robert P Hebbel; Martin H Steinberg; Mark T Gladwin
Journal:  Am J Hematol       Date:  2009-09       Impact factor: 10.047

10.  Improvement in hemolysis and pulmonary arterial systolic pressure in adult patients with sickle cell disease during treatment with hydroxyurea.

Authors:  Matthew Olnes; Amy Chi; Carissa Haney; Rose May; Caterina Minniti; James Taylor; Gregory J Kato
Journal:  Am J Hematol       Date:  2009-08       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.